Question

4. Suppose you are a pharmacologist (a pharmacologist is a scientist who discovers or creates new pharmaceuticals and studies their function and uses) developing a treatment for a disease that results from too much MDH activity. Taking a rational approach to designing a new drug, what kind of a structure might an effective drug have; what kind of a molecule might it resemble, and how would this have the effect of reducing MDH activity?

Answer 1

Step-by-step explanation:

• Malate dehydrogenase catalyzes the oxidation of malate to oxaloacetate, here the NAD+ is diminished to NADH.
• At whatever point the substrate malate will proceed to tie to the hydrophobic hole (dynamic site) of the catalyst, the chemical starts the change of malate to oxaloacetate.
• Here the protein will experience conformational changes to encase the substrate in such a way, that substrate will have least dissolvable presentation and should come conclusion to the dynamic site to experience transformation.

To limit the MDH action:

• We can utilize a simple of malate whose reactant group of three (his-195, Asp-168 and Arg 102, 109 and 171) can be changed so that it ought to proceed to tie to the dynamic site with a similar fondness yet ought not experience any transformation, similar to this you can hinder the dynamic site and diminish the MDH movement.
• In another technique, attempt to look through the basic analogs which can fit into the dynamic site of the chemical to obstruct the action of protein in focused manner or inhibitor which can tie to the site other than dynamic site, to decrease the substrate change.